Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasmin Hashambhoy

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 28, 2005
Neural correlates of reach errorsJörn Diedrichsen, Yasmin Hashambhoy, Tushar Rane, et al.
Molecular Cancer Therapeutics|February 13, 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in TumorsBen Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 28, 2005
Neural correlates of reach errorsJörn Diedrichsen, Yasmin Hashambhoy, Tushar Rane, et al.
Molecular Cancer Therapeutics|February 13, 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in TumorsBen Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of ResponseTimothy A Yap, Justin F Gainor, Margaret K Callahan, et al.
Pageof 1